A recent study indicates that patients who discontinue popular weight-loss injections like semaglutide or tirzepatide can put back on lost weight far faster than those who stop traditional lifestyle regimens.
Findings released in a prominent health publication shows that while obese individuals often shed substantial amounts of their total mass while on the medication, the mass returns at an estimated rate of 0.8 kg per month upon discontinuation.
"Users using such medications need to be aware of the danger of rapid rebound weight gain when the treatment is stopped," cautioned expert Dr. Susan Jebb.
That rate of regain implies a reversion to pre-treatment mass within about a year and a half.
Analyzing Therapies
The analysis, which examined dozens of trials involving thousands of patients, contrasted the outcomes of these new drugs with conventional dieting.
Researchers emphasize that individuals who lose weight through dieting generally experience a slower weight regain—approximately 0.1 kg a month—after stopping.
The Reason for the Quick Regain
Experts propose the mode of action of the drugs explains the accelerated regain.
The injections imitate a body's own chemical called GLP-1, which moderates feelings of fullness.
"Long-term administration of GLP-1 concentrations several times higher than normal could lead to the system to produce less of its own natural hormone, and may also reduce sensitivity to its effects," said Dr. Adam Collins, a nutrition expert.
"Stopping of this GLP-1 'fix' means hunger is unsuppressed, making overeating far more likely."
A Chronic Condition?
The NHS recommend the jabs for people with obesity-related health risks, alongside prescribed diet and exercise modifications.
Professionals argue that, due to the significant potential of relapse, the therapy should be considered life-long.
This perspective is echoed by pharmaceutical companies, who state that the results "highlight the long-term nature of obesity," akin to managing diseases like hypertension.
User Testimonies
People who have discontinued the medication describe a powerful resurgence of cravings.
"I experienced a switch activating and you become ravenous," recalled an individual.
This challenge is compounded if users have not adopted permanent dietary or behavioural modifications during therapy.
Significant Interest
Recent estimates show that a significant number of adults in the UK have tried weight-loss jabs in the past year, with demand being substantial.
- Adoption is greater among women than males.
- The 40s and 50s age group shows the greatest level of interest.
- Many access the medications through private healthcare rather than public health services.
Ultimately, experts caution that while the jabs are potent agents for shedding pounds, they are not a standalone fix and long-term success likely depends on integrated lifestyle changes.
